Alvaro del Real
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alvaro del Real has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ana Isabel Vega
Servicio de Genética, Hospital U.M. Valdecilla, Santander, Spain
2 shared publications - Jose Antonio Riancho
Servicio de Medicina Interna, Hospital U.M. Valdecilla, Santander, Spain; Universidad de Cantabria, Santander, Spain; Instituto de Investigación M. Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain, Spain
2 shared publications - Amelia Ocampo
Departamento de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Spain
1 shared publication - Ana Carina Ferreira
Department of Nephrology, Hospital Curry Cabral – Unidade Local de Saúde de São José , Lisbon
1 shared publication - Aníbal Ferreira
Nephrology Department, Hospital Curry Cabral, Unidade Local de Saúde São José, Lisbon, Portugal
1 shared publication - Eva Martínez de Castro
Servicio de Oncología, Hospital U.M. Valdecilla, Santander, Spain
1 shared publication
Latest Publications
- Open Access
- 28 June 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (9) , 1-5
Vitamin B6 challenge as a tool for detecting ALPL mutations and diagnosing hypophosphatasia
Summary Low serum alkaline phosphatase is the biochemical hallmark of hypophosphatasia. However, it is a non-specific finding. Here we show that a 2-day vitamin B6 challenge is useful to identify carriers of ALPL gene mutations among patients with low serum alkaline phosphatase, with specificity and sensitivity over 90%. Purpose Hypophosphatasia (HPP) is a disorder characterized by deficient activity of the tissue non-specific alkaline phosphatase (ALP) isoenzyme, due to pathogenic variants of the ALPL gene. The biochemical hallmark of HPP is the reduced ALP activity in serum. Pyridoxal 5'-phosphate (PLP), the major circulating form of vitamin B6, is a substrate of ALP. Thus, high PLP levels are commonly used as a diagnostic marker of HPP. This study aimed to assess the diagnostic utility of vitamin B6 supplementation for identifying patients with ALPL variants. Patients and methods We measured PLP in control subjects and patients with low serum ALP, with or without ALPL mutations, at baseline and after a 2-day or 6-day vitamin B6 supplementation (20 mg per day of pyridoxine hydrochloride). Results Although mutation carriers tended to have higher PLP values, up to 33% had baseline levels within the normal range. The vitamin B6 challenge, particularly with the 2-day protocol, improved the diagnostic performance. After 2-day supplementation, all carriers had levels above 500 nmol/l (sensitivity 100%; CI 95–100), whereas only 1 non-carrier surpassed that threshold (specificity 96%; CI 85–100). Conclusion A 2-day vitamin B6 supplementation test may be useful for identifying carriers of ALPL mutations among individuals with unexplained low serum ALP.
- 28 June 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (9) , 1-5
Open AccessVitamin B6 challenge as a tool for detecting ALPL mutations and diagnosing hypophosphatasia
Summary Low serum alkaline phosphatase is the biochemical hallmark of hypophosphatasia. However, it is a non-specific finding. Here we show that a 2-day vitamin B6 challenge is useful to identify carriers of ALPL gene mutations among patients with low serum alkaline phosphatase, with specificity and sensitivity over 90%. Purpose Hypophosphatasia (HPP) is a disorder characterized by deficient activity of the tissue non-specific alkaline phosphatase (ALP) isoenzyme, due to pathogenic variants of the ALPL gene. The biochemical hallmark of HPP is the reduced ALP activity in serum. Pyridoxal 5'-phosphate (PLP), the major circulating form of vitamin B6, is a substrate of ALP. Thus, high PLP levels are commonly used as a diagnostic marker of HPP. This study aimed to assess the diagnostic utility of vitamin B6 supplementation for identifying patients with ALPL variants. Patients and methods We measured PLP in control subjects and patients with low serum ALP, with or without ALPL mutations, at baseline and after a 2-day or 6-day vitamin B6 supplementation (20 mg per day of pyridoxine hydrochloride). Results Although mutation carriers tended to have higher PLP values, up to 33% had baseline levels within the normal range. The vitamin B6 challenge, particularly with the 2-day protocol, improved the diagnostic performance. After 2-day supplementation, all carriers had levels above 500 nmol/l (sensitivity 100%; CI 95–100), whereas only 1 non-carrier surpassed that threshold (specificity 96%; CI 85–100). Conclusion A 2-day vitamin B6 supplementation test may be useful for identifying carriers of ALPL mutations among individuals with unexplained low serum ALP.
- Open Access
- 14 March 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-7
Osteomesopyknosis: A Bone-Sclerosing Disorder that May be Confused with Bone Metastases
Sclerosing bone disorders encompass a range of genetic and acquired diseases. The potential for bone metastases is often a significant concern, especially when multiple discrete lesions are present. Several non-malignant disorders can also produce similar patterns of bone abnormalities. Among these is osteomesopyknosis, a rare condition characterized by multiple sclerotic lesions in the axial skeleton. Only a few cases of this presumably genetic disease have been documented. In this report, we present a new case and review previously published cases to enhance understanding and facilitate recognition of this disorder within the broader category of sclerosing bone diseases.
- 14 March 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-7
Open AccessOsteomesopyknosis: A Bone-Sclerosing Disorder that May be Confused with Bone Metastases
Sclerosing bone disorders encompass a range of genetic and acquired diseases. The potential for bone metastases is often a significant concern, especially when multiple discrete lesions are present. Several non-malignant disorders can also produce similar patterns of bone abnormalities. Among these is osteomesopyknosis, a rare condition characterized by multiple sclerotic lesions in the axial skeleton. Only a few cases of this presumably genetic disease have been documented. In this report, we present a new case and review previously published cases to enhance understanding and facilitate recognition of this disorder within the broader category of sclerosing bone diseases.